

Dostarlimab RUBY

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



No QoL benefit



Serious and disabling adverse effects



Other adjustments



Dostarlimab RUBY

SCORE

CURATIVE



Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival




Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response



Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Gynaecological Malignancies

Therapeutic Indication: Dostarlimab with carboplatin and paclitaxel, followed by single-agent dostarlimab, for adult patients with primary advanced or recurrent endometrial cancer (EC)

Experimental Arm: Dostarlimab + Carboplatin and paclitaxel

Control Arm: Placebo + carboplatin + paclitaxel



